Anbio BiotechnologyNNNN
13F holders, Q1 2026 (March 31)8holders +3
3new positions
0sold out
$25.69avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Anbio Biotechnology Ltd. (NNNN) in their 13F filings, up 3 from Q4 2025. 3 opened new positions and 0 sold out. The largest holders were Geode Capital Management, LLC ($662K), BNP Paribas Financial Markets ($267K) and Morgan Stanley ($189K).
- Company
- Anbio Biotechnology Ltd.
- CUSIP
- G0367B105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $7K |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 20,486 shares bought, net +20,486 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Geode Capital Management, LLC | 0.00% | No change | 25,763 | $662K |
| BNP Paribas Financial Markets | 0.00% | Add +940.0% | 10,400 | $267K |
| Morgan Stanley | 0.00% | Add +26107.1% | 7,338 | $189K |
| UBS Group AG | 0.00% | Add +122.5% | 6,339 | $163K |
| EverSource Wealth Advisors, LLC | 0.00% | New | 266 | $7K |
| Wells Fargo & Company | 0.00% | No change | 100 | $3K |
| Bare Financial Services, Inc | 0.00% | New | 15 | $385 |
| Blue Trust, Inc. | 0.00% | New | 5 | $128 |
"% of holder's portfolio" is NNNN's weight in each manager's 13F, not the share of Anbio Biotechnology Ltd. the manager owns.